Fluproquazone in the management of strains and sprains.
A double-blind randomized trial was carried out in 59 patient suffering from moderately severe to severe strains and sprains to compare the efficacy of 4-(p-fluorophenyl)-1-isopropyl-7-methyl-2(1H)-quinazolinone (fluproquazone) in the relief of pain. Patients received either 50 mg or 100 mg fluproquazone up to 6 times daily for 3 days. The results of subjective assessments showed that after 2 days pain had either completely resolved or markedly improved in all patients. Both treatments were equally effective in relieving both spontaneous pain and pain on movement after 1 and 2 days. No differences were found between the two groups in the patients' overall evaluation of treatment or physicians' assessment of therapeutic response. Both dosage were well tolerated during the short-term trial.
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011799:Quinazolines / Q000627:therapeutic use*; D052999:Quinazolinones; D013180:Sprains and Strains / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010919:Placebos; D011799:Quinazolines; D052999:Quinazolinones; C023491:fluproquazone